Aim-This study aims to examine the prevalence of alcohol and/or other drugs (AOD) in a large sample of fatally injured drivers.
INTRODUCTION
Public concern about drugged driving has heightened in recent years, fueled in part by high profile crashes [1, 2] , rising consumption of prescription drugs, and increased morbidity and mortality related to prescription drug abuse [3] [4] [5] [6] [7] [8] [9] [10] [11] . In the United States, from 1991 to 2007, opiate prescriptions rose from approximately 40 million to around 180 million [6] . National estimates of emergency department visits involving illicit drugs, alcohol, and pharmaceuticals show an almost two-fold increase between 2004 and 2009 [12] . The 2009 National Survey on Drug Use and Health estimates that 10.5 million persons 12 or more years of age drove under the influence of illicit drugs in the prior year [12] . The Office of National Drug Control Policy, along with the Department of Transportation and the National Institute on Drug Abuse, has identified driving under the influence of drugs as a priority area for drug control research and interventions [13] [14] [15] [16] .
Polydrug use by drivers, i.e., the use of two or more drugs concurrently, is of particular concern as the interaction effects of different drug combinations may be significantly greater than the effects of using individual drugs alone [17] [18] [19] [20] [21] . Compared with the use of alcohol or cannabis alone, the combined effect of these substances poses excess risk of impairments in driving performance and crash involvement [18, 22] . Studies have revealed that the effect of cannabis on impairment in driving performance is greater in combination with amphetamines, benzodiazepines, and opiates than for these other drugs alone [19, 22, 23] . Similar findings have been reported for benzodiazepines used in combination with opiates [22] .
Epidemiologic data on polydrug use in drivers are sparse. Results from roadside surveys indicate that about 2% of drivers in the United States and 1% of drivers in Europe are positive for two or more drugs [24, 25] . Toxicological testing data for drivers injured in motor vehicle crashes suggest that up to 25% tested positive for multiple drugs, with alcohol, cannabis, and opiates being the most frequently detected substances [26, 27] . Studies of drivers arrested for suspected impaired driving in Scotland and Finland suggest an increasing trend in polydrug use [28, 29] . A recent cross-sectional survey of fatally injured drivers in four European countries found that the prevalence of polydrug use varied from 6.4% in Portugal to 15.2% in Norway [30] . Previous studies documenting the prevalence of polydrug use in injured drivers in the United States were limited to small sample sizes from single institutions. In the present study, we aim to examine the prevalence of alcohol and/or other drugs (AOD) and specific drug combinations in a large sample of fatally injured drivers by capitalizing on recently available comprehensive toxicological testing data in 14 states.
METHODS

Data source
Data for this study came from the Fatality Analysis Reporting System (FARS). Compiled by the National Highway Traffic Safety Administration, FARS is a census of fatal traffic crashes occurring within the United States and includes all crashes involving a motor vehicle traveling on a public road and resulting in a fatality within 30 days of the crash [31] . This data system contains detailed data on the circumstances, vehicles, and people involved in the crash. Data are abstracted from police reports, state administrative files, and medical records by trained analysts using standard forms and protocols. Data are monitored using specified quality control procedures [32] . Data elements include driver characteristics, such as, sex, race, ethnicity, drug and alcohol test results. Crash circumstances including vehicle type, day, time, and year of crash are also recorded. Although FARS started recording testing results for non-alcohol drugs since 1991, drug testing was performed on only about 30% of fatally injured drivers nationwide. Drug testing on fatally injured drivers, however, has become routine in an increasing number of states in recent years [10] .
Study sample
The study sample consisted of 22,649 drivers who died within one hour of the crash between January 1, 2005 and December 31, 2009 in states that performed toxicological testing on more than 80% of their fatally injured drivers (California, Connecticut, Illinois, Kentucky, Maryland, Montana, New Hampshire, New Jersey, North Dakota, Ohio, Pennsylvania, Vermont, Washington, and West Virginia). Despite higher than 80% testing rates, data from North Carolina and New Mexico were excluded from the study sample because test results recorded in FARS for these two states were deemed unreliable [32, 33] . Of the 22,649 drivers in the study sample, 2,499 (11.0%) were excluded from the analysis due to the lack of drug testing data. Drivers who survived more than one hour after the crash (n=9,160) or with missing time of death information (n=225) were excluded from this study because of concerns about the accuracy and reliability of drug testing data for these drivers.
Statistical analysis
To assess selection bias resulting from incomplete drug testing, drivers with and without toxicological results were examined by driver characteristics (age, sex, race, ethnicity, driver type, driving while intoxicated (DWI) conviction in the past 3 years, crash within the past 3 years, and blood alcohol concentration (BAC)), and crash circumstances (number of vehicles involved, day of crash, time of day, and year), as well as time until death and the location of death. Race was grouped as White, Black, Asian (Chinese, Japanese, Hawaiian, Filipino, Asian Indian, Other Indian, Korean, Samoan, Vietnamese, Guamanian, Other Asian, and Pacific Islander), Native American, Other (multiple races and all other races), and Unknown. Ethnicity was categorized as Hispanic, Non-Hispanic and Unknown. Driver types were categorized as motor carrier, defined as a driver of a motor vehicle with a gross vehicle weight of 26,000 pounds or greater, versus any other type of road vehicle [34] . BAC was measured in grams per deciliter. The number of vehicles involved in the crash was categorized into whether one or two or more vehicles were involved. Day of crash was categorized into whether the crash occurred on a weekday (Monday to Thursday) or a weekend (Friday to Sunday). Time of crash was grouped as day (crashes occurring between 7:00 am and 6:59 pm) and night (crashes occurring between 7:00 pm and 6:59 am) [30] . Chi-square tests with an alpha level of 0.05 were used to determine whether drivers with and without drug test results differed by driver characteristics and crash circumstances.
The prevalence of drug involvement in fatally injured drivers was tabulated by drug class. Using robust-variance Poisson regression, multivariable-adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) were estimated separately for single-drug use, polydrug use, and any drug use [35] . Variables that were statistically significant in bivariable analyses, along with driver demographic characteristics, were included in each multivariable model. Data analyses were performed using Statistical Analysis Software, version 9.2 (SAS Institute, Inc., Cary North Carolina) and Stata/SE, version 11.2 (StataCorp LP, College Station, Texas).
Drug testing assessments
Drug tests were performed using chromatography and radioimmunoassay techniques based on blood and/or urine specimens [27, 36] . Up to four drugs, including alcohol, were recorded for each driver. When multiple drugs were reported, non-alcohol drugs were logged in the FARS data in the following priority order: narcotics, depressants, stimulants, marijuana and other licit drugs [27] . Drugs were categorized according to the FARS coding manual [37] and grouped into the following categories: alcohol, cannabinol, stimulant, narcotic, depressant (exclusive of alcohol), hallucinogen, phencyclidine (PCP), anabolic steroid, inhalant, and "other" drugs. Due to small numbers, the hallucinogen, PCP, anabolic steroid, and inhalant categories were combined. "Other" drugs include drugs not classified as the above categories in the FARS coding manual [37] . These are generally other legal drugs (such as beta-blockers, anti-epileptics, antihistamines or antidepressants) that may or may not impair driving ability [27] . Drugs administered after the crash were not included [10] . Polydrug use was operationally defined as testing positive for two or more substances, with alcohol being treated as a drug. If a driver tested positive for a drug and its metabolite, the driver was only categorized as being positive for the parent drug. For example, if a driver tested positive for methamphetamine and amphetamines, the driver was categorized as testing positive for methamphetamine only.
Drug testing protocols might vary from state to state [38, 39] . Some states tested for fewer drugs than others [40] . The testing methods and specimens might not be exactly the same across the states. The possible bias resulting from different specimens, however, was unlikely to pose a serious threat to the validity of this study given that 94% of the study sample had at least one test based on a blood specimen.
RESULTS
Representativeness of the study sample
Overall, 89% of drivers in the study sample were tested for AOD. Drivers for whom laboratory drug testing results were available and drivers who were excluded from the analysis due to the lack of drug testing data were similar with regard to sex, driver type, the number of vehicles involved in the crash, crash in the past 3 years, day of crash, time until driver death, and location of driver death (Table 1) . Notable exceptions to the comparability between the two groups were that drivers who were tested were more likely to be 25-34 years of age and white, have a known ethnicity, be alcohol-positive (i.e., BAC ≥ 0.01 g/dL), and be involved in night-time crashes. Drivers who were fatally injured in 2005 were more likely to have incomplete drug testing data than in subsequent years (Table 1) . Of the 20,150 drivers included in the analysis, 94% had at least one drug test result based on a blood specimen.
Prevalence of drug use
Of the 20,150 drivers who were tested for drugs, 11,550 (57.3%, 95% CI: 56.6-58.0%) were positive for at least one drug, including 7,549 (37.5%) positive for one drug and 4,001 (19.9%, 95% CI: 19.3-20.4%) positive for two or more drugs (Table 2) . Alcohol was the most commonly detected drug, present alone or in combination with one or more other drugs in 40.2% (95% CI 39.5-40.8) of the tested drivers. Non-alcohol drugs were detected in 31.8% of drivers (95% CI: 31.1-32.4). Cannabinols (10.5%, 95% CI: 10.0-10.9) were the most frequently detected non-alcohol drug, followed by stimulants (9.0%, 95% CI: 8.6-9.4), narcotics (5.7%, 95% CI: 5.4-6.0), and depressants (4.0%, 95% CI: 3.7-4.2) ( Table 2 ). The specific drug combinations commonly detected were alcohol with cannabinols, cocaine, or methamphetamine, accounting for 32.4% of all polydrug use. For drivers testing positive for three drugs, the most frequently detected drug classes were alcohol, cannabinols and stimulants, with cocaine being the most commonly detected stimulant (Table 2) .
Male drivers had significantly higher prevalence rates of single-drug use and two-drug use than female drivers (Table 2) . Overall, 60.1% of male drivers and 47.5% of female drivers tested positive for at least one drug ( Table 2 ). The overall prevalence of non-alcohol drugs was similar between male (31.8%, 95% CI: 31.1-32.6%) and female drivers (31.5%, 95% CI: 30.2-32.9%). The prevalence of specific drugs, however, differed significantly between sexes, with men being more likely to use alcohol, cannabinols, and stimulants and women being more likely to use narcotics, depressants, and other drugs (Figure 1 ). Native American drivers had the highest prevalence of drug use (83.7%, including 37.8% of single-drug use and 45.9% of polydrug use). Non-Hispanic drivers, non-motor carrier drivers, drivers involved in crashes in the prior 3 years, drivers involved in single-vehicle crashes, and drivers with a DWI within the prior 3 years were more likely to test positive for a single-drug and for polydrugs ( 
DISCUSSION
Results of this study indicate that more than half (57%) of fatally injured drivers in the United States had been using at least one drug and 20% had been using two or more drugs. The prevalence of single-drug use and polydrug use reported in this study is generally consistent with previous reports from the United States and Canada [26, 27, 41] . The large sample size of this study made it possible to examine the specific drugs involved in polydrug use and the driver characteristics associated with drug use. Despite the decline of alcoholrelated motor vehicle crashes in recent years [42, 43] , alcohol remains the most commonly detected drug, present in 40% of fatally injured drivers dying within one hour of the crash. In two-and three-drug combinations, alcohol was most frequently detected in the presence of marijuana and stimulants, with cocaine and methamphetamine being the most commonly used stimulant drugs.
The prevalence of single-drug use and polydrug use varies significantly with driver characteristics. In addition to several demographic variables known to be associated with drug use, such as sex, age, race, and ethnicity, this study adds more evidence for DWI history as a valid marker of subsequent use of alcohol and other drugs and for the effectiveness of mandatory drug testing programs in improving driving safety. With adjustment for demographic characteristics, drivers with a DWI history in the past three years are 44% more likely than drivers without a DWI history to test positive for single-drug use, and 81% more likely to test positive for two or more drugs. Furthermore, motor carrier drivers, who are subject to mandatory alcohol and drug testing programs, were substantially less likely than other drivers to test positive for alcohol and other drugs. Similar findings have been reported in previous research [33, 44, 45] , suggesting that mandatory alcohol and drug education, testing, and vehicle interlocks should be part of the punitive consequences of DWI and driving under the influence [46] .
Debate exists over how best to classify medications and drugs in relation to driving safety, as it can be difficult to determine whether a substance is used as prescribed, or as intended [47] . Detection of drugs may indicate the use of illegal drugs, prescription drugs, or overthe-counter drugs, but does not necessarily imply that a drug was misused. In this study, the "other" drug category may include substances not considered to impair driving performance, but "other" drug use nevertheless is significant because the implications of ingesting multiple substances, illicit, prescription, or over-the-counter are not fully understood [19, 20, [48] [49] . Therefore, understanding what drugs may be included in the "other" drug category is important. A study of crash fatalities in the United Kingdom shows that a range of prescription and over-the-counter medications are classified as "other", including anti-convulsants, anti-histamines, anti-inflammatories, anti-psychotics, cardiac drugs and diabetic drugs [50] . Drugs of abuse captured as "other" drugs in the UK study [50] , i.e., gamma hydroxybutyric acid, benzylpiperazine, and ketamine, are categorized by the FARS coding manual and the present study as depressants, "other" drugs, and hallucinogens, respectively.
Although this study provides compelling evidence about the prevalence and correlates of AOD in driver fatalities, it is subject to several limitations. First, the study sample is limited to fatally injured drivers who died within one hour of the crash in states where toxicological testing is performed on a routine basis. Although the inclusion and exclusion criteria for selecting the study subjects help enhance the internal validity of the study, they may reduce the generalizability of the findings across different driver population groups and geographic regions. The prevalence of AOD detected in non-fatally injured drivers [51] and in roadside surveys [24] is generally much lower than reported in this study, implying that use of alcohol and other drugs is associated with increased injury severity and heightened crash risk [52, 53] .
Second, this study examined drug use, which may or may not correspond to acute impairment. There is no uniformly accepted definition of impairment by different drugs [46, 54] . Variations in individual tolerance, pharmacological characteristics of different drugs, and dose make it difficult to identify drug impairment [1, 38, 55] . Discerning drug impairment from drug involvement is not possible from these data as the amount of drug present was not available in the FARS data, and because the physiological effects differ by drug and the effects of drugs are more varied and less well defined than, for example, alcohol [38, 39] . Legal definitions of drug impairment differ from state to state. As of 2008, impairment related to drugs was defined in 15 states as operating a motor vehicle with any detectable level of an illicit drug or its metabolites [3] . Other states have characterized impairment as substance use that reduces a driver's ability to operate a vehicle safely by diminishing motor skills and reaction time and altering perception [3, 56] . Moreover, drug detection could represent the presence of a drug metabolite from past use [54] . A person can test positive for a non-alcohol drug (e.g., marijuana) several weeks after use. Therefore, a positive test result identified drug use, but does not necessarily indicate that the user was impaired by the drug at the time of the test. Finally, it was not possible to discern if polydrug use reflected concurrent or simultaneous ingestion of drugs. Simultaneous polydrug use has been shown to confer greater morbidity and negative health consequences [57, 58] .
The complexity involved with studying drug impairment has led researchers to put forth a number of recommendations to more effectively examine drugged driving, including training of coroners, pathologists, and toxicologists to ensure complete laboratory analyses (preferably using whole blood) for a standardized list of drugs [25, 30, 59] . The guidelines will likely facilitate research by clarifying what drugs are categorized in the other drug classification and helping to identify interaction effects of different drug combinations on driving safety [25, 30, 59, 60] .
The results of this study indicate that use of AOD is pervasive among fatally injured drivers in the United States. Alcohol is the most frequently used drug both alone and in combination with other drugs. In view of the magnitude of AOD in fatally injured drivers, expanding routine drug testing of drivers involved in motor vehicle crashes is warranted. For nonfatally injured drivers, an initial screening of oral fluid may help decide whether to obtain a blood or urine sample [61] . Screening oral fluid would allow a wider group of drivers to be studied and may serve as a deterrent against driving under the influence of alcohol and other drugs.
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